News

Stay up to date on NKGen Biotech’s company news and announcements.

In the News

June 25, 2024

Santa Ana Biotech company gets green light from FDA to continue promising new Alzheimer’s treatment – KCBS/KCAL News Los Angeles (Video link)

Press Releases

2025

NKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy

July 10, 2025

NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer’s Trial with Activation of Clinical Sites in Canada and Florida

June 23, 2025

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations

May 8, 2025

NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

May 7, 2025

NKGen Biotech To Present on the Use of Troculeucel for Alzheimer’s and Parkinson’s Disease at the 7th China International Biotechnology Conference & Exhibition

April 14, 2025

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)

April 7, 2025

NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)

March 25, 2025

NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit

March 13, 2025

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

March 4, 2025

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

March 3, 2025

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

February 21, 2025

NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site

February 19, 2025

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease

February 13, 2025

NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease

February 12, 2025

2024

NKGen Biotech Selected as Stalking Horse Bidder for NKMax

December 2, 2024

NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

October 29, 2024

NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)

October 15, 2024

NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

October 8, 2024

NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial

September 12, 2024

NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 3, 2024

NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference

July 30, 2024

NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference

July 18, 2024

NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors

July 15, 2024

NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024

June 12, 2024

NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024

June 3, 2024

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024

NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease

May 20, 2024

NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition

May 16, 2024

NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease

April 29, 2024

NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

April 25, 2024

NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

April 24, 2024

NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

April 18, 2024

NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs

April 11, 2024

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

March 25, 2024

NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference

March 4, 2024

2023

NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease

December 28, 2023

NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

December 27, 2023

NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

November 14, 2023

NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

October 26, 2023

NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

October 24, 2023

NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

October 19, 2023

NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023

October 17, 2023

NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023

October 11, 2023

NKGen Biotech, Inc. Announces Closing of Business Combination

October 2, 2023

NKGen Biotech to Present at the Cantor Fitzgerald Global Healthcare Conference 2023

September 21, 2023

NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors

August 24, 2023

Graf Acquisition Corp. IV And NKGen Biotech, Inc. Announce Effectiveness Of Form S-4 For Proposed Business Combination

August 15, 2023

NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company

August 9, 2023

NKGen Biotech Presents Interim Phase I Trial Data at 2023 Alzheimer’s Association International Conference

July 17, 2023

NKGen Announces Poster Presentation at the 2023 Alzheimer’s Association International Conference

July 10, 2023

NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event

July 6, 2023

NKGen Biotech to Present at the 2nd International Alzheimer’s Disease & Dementia Conference 2023

June 13, 2023

NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

June 5, 2023

NKGen Announces Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023

NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

May 2, 2023

NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV

April 14, 2023

Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination

March 23, 2023

NKGen Biotech Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Natural Killer Cell Therapies Targeting Neurodegenerative Diseases

March 8, 2023

NKGen Biotech Announces Appointment of Chief Financial Officer

February 24, 2023

NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer

January 10, 2023

2022

NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson’s Disease

November 4, 2022

NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors

October 17, 2022

NKGen Biotech Announces Publication in Journal of Cancer Research and Cellular Therapeutics on Durable Response for SNK01 in Advanced Sarcoma

September 21, 2022

NKGen Biotech to Present at the Baird 2022 Global Healthcare Conference

September 7, 2022

NKGen Biotech To Present SNK01 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2022

September 6, 2022

NKGen Biotech to Participate in Truist Securities Cell Therapy Symposium

June 21, 2022

NKGen Biotech To Present SNK01 Clinical Data at the 2022 ASCO Annual Meeting

May 26, 2022

NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

May 5, 2022

NKGen Biotech Announces Three SNK01 Abstracts to be Presented at the 2022 ASCO Annual Meeting

May 2, 2022

2021

NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

November 15, 2021

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01

November 8, 2021

NKGen Biotech Announces Acceptance of SNK01 Abstract for Presentation at the 2021 Connective Tissue Oncology Society Annual Meeting

October 20, 2021

NKGen Biotech to Participate in the Virtual Solebury Trout Fall Private Company Showcase Co-hosted with BMO

October 7, 2021

NKMax Announces SNK01 Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

October 4, 2021

NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC

April 13, 2021

NKMax America Announces Corporate Name Change to NKGen Biotech

April 2, 2021

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

March 31, 2021

2020

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy

October 20, 2020

NKMax America Announces a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer

September 8, 2020

NKMax America Receives FDA Clearance to Amend its Current Phase I Monotherapy Trial to Include an Additional New Cohort of SNK01 + Checkpoint Inhibitor in Refractory Solid Tumors.

August 31, 2020

NKMax America Receives FDA Clearance of IND for Phase I/2a Trial of their Natural Killer Cell Therapy (SNK01) in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced/Metastatic HER2- or EGFR- Expressing Cancers

June 2, 2020

NKMax America Presents Promising Clinical Research Findings at 2020 ASCO Virtual Conference

May 29, 2020

NKMax America To Present Data from Natural Killer Cell Immunotherapy Clinical Program at the ASCO20 Virtual Scientific Program

April 30, 2020

NKMax America Announces Acceptance of Three Abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting

March 31, 2020

NKMax America to Present at the Upcoming NIH-AACR Cancer, Autoimmunity, and Immunology Conference

March 17, 2020

NKMax America to Present at Immuno-Oncology Summit Europe 2020

March 9, 2020

NKMax America to Present Corporate Overview at the Cowen & Company 40th Annual Health Care Conference

March 3, 2020

2019

NKMax America Announces New cGMP Manufacturing Facility for Production of SNK Cell Therapy

September 9, 2019

NKMax America Doses First Subject in Phase I Trial of SNK in Patients with Refractory Cancer

August 13, 2019

NKMax America to Present at 2019 Innate Immunity Conference

March 19, 2019

NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer

March 5, 2019

NKGen Biotech Events

Check back soon for upcoming events!

NKGen on Social Media

Follow NKGen on social media to keep up-to-date on the latest company news and the science of Natural Killer cells!

Science

NK Cell Function & Disease

Scientific Publications

NKGen Biotech, Inc.

Corporate Headquarters
3001 Daimler Street
Santa Ana, CA 92705
Phone: 949-396-6830
Email: info@nkgenbiotech.com

News

In the News

Press Releases

Subscribe to NKGen News Updates

NKGen Biotech Events

NKGen on Social Media